Over ten years ago, the economic concept of the ‘BRIC’ countries- Brazil, Russia, India and China – was formed, and it’s pretty much all we’ve heard about ever since. Yet earlier this year, the very same man who coined the term – Jim O’Neill, chief economist at Goldman Sachs…
Mexico Despite being in the Mexican market for over twenty years, biosimilars have never been regulated as a separate entity. They have always been regulated as simply another category of generic medicines. “This enabled almost unmonitored competition from China, India, South Korea and other fast-growing countries, which sometimes caused more damage…
Dr. Reddy's Laboratories Romania You have been the first employee to start Dr. Reddy’s in Romania and when we look back at those early years, we see that a portfolio of gastroenterology and analgesics was chosen to enter the market… Why, in the first place, were these therapeutic areas targeted? At that time, the…
China Medical University Healthcare System Many key figures from the pharmaceutical industry have told us that the hospitals in Taiwan are the keystone to the country’s healthcare industry: the hospitals provide a very important service linking the latest innovations from pharmaceutical companies to the people, and helping encourage growth and innovation. I’d like to start…
ScinoPharm 2010 is ScinoPharm’s thirteenth year of operations. Thirteen does not seem to be an unlucky number for you as your company is doing particularly well at the moment. Perhaps you could start by telling our readers a little bit about the recent history of ScinoPharm and the good times that…
Lonza UK Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in the UK primarily at two sites; Slough and Cambridge. The Slough site is the main centre for our UK operations…
Martindale Pharma Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When I was invited to join Martindale I was tasked with the mission to identify a strategy for the company and…
Fabiol Apart from MNCs, there are many local businesses that are rather strong in the Romanian pharmaceutical market. Could you give our readers an idea of their main strengths? There is great potential to source raw materials from within Romania. Romanian manufacturers that can easily work with these materials are not…
Eisai Europe As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary Hendler (GH): Eisai are currently present in 17 European markets as Eisai and several others via distributors. However it is…
Roche Serbia Roche is one of the oldest multinational pharmaceutical companies here in Serbia. How do you think your history in the country gives you an advantage today as a company? We are very proud of the heritage that Roche has in Serbia, being present here for many decades, from the first…
National Agency for Medicines and Medical Devices (NAMMD) of Romania Under various former names for over five decades, the Agency has undoubtedly played a key role in setting a regulatory framework for Romania’s pharmaceutical market. Over these five decades, thorough changes in the political regime, subsequent regulatory changes, the emergence of new institutions, and many other factors have drastically changed…
See our Cookie Privacy Policy Here
